Latest Safety News

Page 7 of 252
PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
Ada Torres
Ada Torres
29 Oct 2026
AVADA Group’s FY27 first-quarter customer receipts rose 38% to A$66.4 million, but cash conversion remained tight after A$5.1 million in Payday Super and prior-period ATO payments. The traffic management operator ended September with A$3.31 million in cash and A$13.84 million of unused facilities.
Victor Sage
Victor Sage
29 Oct 2026
Everlast Minerals has moved from a maiden export to a second China shipment and a much larger trial-commercial cargo planned after quarter end. The progress comes as the company commissions new processing infrastructure, but commercial production remains unestablished and cash stood at A$2.252 million.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Element 25 has completed the enabling works for its planned 1.1Mtpa Butcherbird manganese expansion, moving the project towards major plant construction. Financial close on the AU$50 million NAIF package remains unfinished, leaving funding and contract finalisation as the next key tests.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
WA1 Resources has reported further high-grade niobium intersections at Luni as it works towards completing its Pre-Feasibility Study this quarter. The project enters its next phase with A$113.2 million in cash, a commissioned airstrip and key 2026 fieldwork largely complete.
Maxwell Dee
Maxwell Dee
28 Oct 2026

Browse the archive

Full archive